Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Selank | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril). | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 14-21 day cycles with equal rest periods. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin (from IgG heavy chain) with a Pro-Gly-Pro extension for metabolic stability. It allosterically modulates GABA-A receptors, enhancing GABA binding and GABAergic neurotransmission. Selank modifies mRNA levels of 84 genes involved in GABAergic neurotransmission in the frontal cortex, enhances enkephalinase inhibition (increasing endogenous enkephalin levels), and modulates serotonergic and noradrenergic systems to produce anxiolytic and nootropic effects.
Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril).
Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night.
14-21 day cycles with equal rest periods.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →